[breadcrumb_custom]

Esperion Therapeutics Inc. (NASDAQ: ESPR) In 2024: Will It Be Worth Your Money?

In the last trading session, 3.84 million Esperion Therapeutics Inc. (NASDAQ:ESPR) shares changed hands as the company’s beta touched 0.81. With the company’s per share price at $2.58 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $439.68M. ESPR’s last price was a discount, traded about -161.24% off its 52-week high of $6.74. The share price had its 52-week low at $0.70, which suggests the last value was 72.87% up since then. When we look at Esperion Therapeutics Inc.’s average trading volume, we note the 10-day average is 5.27 million shares, with the 3-month average coming to 0.63.

Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information

With action 17.81%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -13.71%, with the 5-day performance at 17.81% in the green. However, in the 30-day time frame, Esperion Therapeutics Inc. (NASDAQ:ESPR) is -6.18% down. Looking at the short shares, we see there were 20.07 million shares sold at short interest cover period of 2.52 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Esperion Therapeutics Inc. (ESPR) estimates and forecasts

Data shows that the Esperion Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 53.57% over the past 6 months, a 41.19% in annual growth rate that is considerably higher than the industry average of 11.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.80%. The 2024 estimates are for Esperion Therapeutics Inc. earnings to increase by 42.41%, but the outlook for the next 5-year period is at 16.90% per year.

ESPR Dividends

Esperion Therapeutics Inc. is expected to release its next quarterly earnings report between February 19 and February 23.

Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.28% of Esperion Therapeutics Inc. shares while 46.80% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 46.93%. There are 46.80% institutions holding the Esperion Therapeutics Inc. stock share, with Wasatch Advisors LP the top institutional holder. As of Jun 29, 2023, the company held 12.28% of the shares, roughly 13.14 million ESPR shares worth $18.26 million.

Armistice Capital, LLC holds the second largest percentage of outstanding shares, with 8.59% or 9.19 million shares worth $12.78 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Wasatch Small Cap Growth Fund and Wasatch Ultra Growth Fund. With 4.06 million shares estimated at $5.64 million under it, the former controlled 3.80% of total outstanding shares. On the other hand, Wasatch Ultra Growth Fund held about 3.36% of the shares, roughly 3.6 million shares worth around $5.0 million.

On Key

Related Posts